BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 31041733)

  • 1. Association of Early Systemic Corticosteroid Therapy with Mortality in Patients with Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis: A Retrospective Cohort Study Using a Nationwide Claims Database.
    Morita K; Matsui H; Michihata N; Fushimi K; Yasunaga H
    Am J Clin Dermatol; 2019 Aug; 20(4):579-592. PubMed ID: 31041733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retrospective study of 213 cases of Stevens-Johnson syndrome and toxic epidermal necrolysis from China.
    Yang L; Shou YH; Li F; Zhu XH; Yang YS; Xu JH
    Burns; 2020 Jun; 46(4):959-969. PubMed ID: 31898979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A 10-year retrospective cohort study of the management of toxic epidermal necrolysis and Stevens-Johnson syndrome in a New South Wales state referral hospital from 2006 to 2016.
    Chan L; Cook DK
    Int J Dermatol; 2019 Oct; 58(10):1141-1147. PubMed ID: 30908601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose intravenous immunoglobulins in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis in Chinese patients: a retrospective study of 82 cases.
    Chen J; Wang B; Zeng Y; Xu H
    Eur J Dermatol; 2010; 20(6):743-7. PubMed ID: 20952352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of Plasmapheresis vs Immunoglobulin as First Treatment After Ineffective Systemic Corticosteroid Therapy for Patients With Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.
    Miyamoto Y; Ohbe H; Kumazawa R; Matsui H; Fushimi K; Yasunaga H; Ohta B
    JAMA Dermatol; 2023 May; 159(5):481-487. PubMed ID: 36884227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination therapy of intravenous immunoglobulin and corticosteroid in the treatment of toxic epidermal necrolysis and Stevens-Johnson syndrome: a retrospective comparative study in China.
    Yang Y; Xu J; Li F; Zhu X
    Int J Dermatol; 2009 Oct; 48(10):1122-8. PubMed ID: 19775409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of Combination Therapy With Etanercept and Systemic Corticosteroids for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Multicenter Observational Study.
    Zhang J; Lu CW; Chen CB; Wang CW; Chen WT; Cheng B; Ji C; Chung WH
    J Allergy Clin Immunol Pract; 2022 May; 10(5):1295-1304.e6. PubMed ID: 35131514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in children: 20 years study in a tertiary care hospital.
    Techasatian L; Panombualert S; Uppala R; Jetsrisuparb C
    World J Pediatr; 2017 Jun; 13(3):255-260. PubMed ID: 27650525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of prior corticosteroid use on the clinical course of Stevens-Johnson syndrome and toxic epidermal necrolysis: a case-control analysis of patients selected from the multinational EuroSCAR and RegiSCAR studies.
    Lee HY; Dunant A; Sekula P; Mockenhaupt M; Wolkenstein P; Valeyrie-Allanore L; Naldi L; Halevy S; Roujeau JC
    Br J Dermatol; 2012 Sep; 167(3):555-62. PubMed ID: 22639874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A retrospective analysis of Stevens-Johnson syndrome/toxic epidermal necrolysis treated with corticosteroids.
    Liu W; Nie X; Zhang L
    Int J Dermatol; 2016 Dec; 55(12):1408-1413. PubMed ID: 27652522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The nationwide epidemiological survey of Stevens-Johnson syndrome and toxic epidermal necrolysis in Japan, 2016-2018.
    Sunaga Y; Kurosawa M; Ochiai H; Watanabe H; Sueki H; Azukizawa H; Asada H; Watanabe Y; Yamaguchi Y; Aihara M; Mizukawa Y; Ohyama M; Hama N; Abe R; Hashizume H; Nakajima S; Nomura T; Kabashima K; Tohyama M; Takahashi H; Mieno H; Ueta M; Sotozono C; Niihara H; Morita E; Kokaze A
    J Dermatol Sci; 2020 Dec; 100(3):175-182. PubMed ID: 33046331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and Validation of a Risk Prediction Model for In-Hospital Mortality Among Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis-ABCD-10.
    Noe MH; Rosenbach M; Hubbard RA; Mostaghimi A; Cardones AR; Chen JK; Cotliar J; Davis MDP; Dominguez A; Fox LP; Hughey LC; Kaffenberger BH; Kroshinsky D; Kwong BY; Miller DD; Musiek A; Ortega-Loayza AG; Sharon VR; Shinkai K; Summers EM; Wanat KA; Wetter DA; Worswick S; Margolis DJ; Gelfand JM; Micheletti RG
    JAMA Dermatol; 2019 Apr; 155(4):448-454. PubMed ID: 30840032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Nationwide Population-Based Study Using National Health Insurance Database in Korea.
    Yang MS; Lee JY; Kim J; Kim GW; Kim BK; Kim JY; Park HW; Cho SH; Min KU; Kang HR
    PLoS One; 2016; 11(11):e0165933. PubMed ID: 27835661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retrospective analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis in 87 Japanese patients--Treatment and outcome.
    Yamane Y; Matsukura S; Watanabe Y; Yamaguchi Y; Nakamura K; Kambara T; Ikezawa Z; Aihara M
    Allergol Int; 2016 Jan; 65(1):74-81. PubMed ID: 26666483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stevens-Johnson syndrome and toxic epidermal necrolysis: a 10-year experience in a burns unit.
    Houschyar KS; Tapking C; Borrelli MR; Nietzschmann I; Puladi B; Ooms M; Rein S; Houschyar M; Duscher D; Maan ZN; Reumuth G; Branski LK; Modabber A; Kluwig D; Schmitt L; Philipp-Dormston WG; Yazdi AS; Siemers F
    J Wound Care; 2021 Jun; 30(6):492-496. PubMed ID: 34121430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Analysis of treatments and deceased cases of severe adverse drug reactions--analysis of 46 cases of Stevens-Johnson syndrome and toxic epidermal necrolysis].
    Yamane Y; Aihara M; Tatewaki S; Matsukura S; Kanbara T; Yamakawa Y; Ikezawa Z
    Arerugi; 2009 May; 58(5):537-47. PubMed ID: 19487835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical features of Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Sato S; Kanbe T; Tamaki Z; Furuichi M; Uejima Y; Suganuma E; Takano T; Kawano Y
    Pediatr Int; 2018 Aug; 60(8):697-702. PubMed ID: 29888432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of additional i.v. immunoglobulin to steroid therapy in Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Aihara M; Kano Y; Fujita H; Kambara T; Matsukura S; Katayama I; Azukizawa H; Miyachi Y; Endo Y; Asada H; Miyagawa F; Morita E; Kaneko S; Abe R; Ochiai T; Sueki H; Watanabe H; Nagao K; Aoyama Y; Sayama K; Hashimoto K; Shiohara T;
    J Dermatol; 2015 Aug; 42(8):768-77. PubMed ID: 25982480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis in Japan from 2000 to 2006.
    Yamane Y; Aihara M; Ikezawa Z
    Allergol Int; 2007 Dec; 56(4):419-25. PubMed ID: 17713361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous Immunoglobulin Combined With Corticosteroids for the Treatment of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A Propensity-Matched Retrospective Study in China.
    Yang L; Shou YH; Li F; Zhu XH; Yang YS; Xu JH
    Front Pharmacol; 2021; 12():750173. PubMed ID: 35115922
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.